Skip to main content

Business

Business, Case Study
The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab
Diana Brixner, RPh, PhD; Gary Oderda, PharmD, MPH; Joseph Biskupiak, PhD, MBA; Douglas S. Burgoyne, PharmD, FAMCP; Steven G. Avey, RPh, MS, FAMCP; Steven R. Feldman, MD, PhD
Read More
Business, Original Research
Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
Ken LaPensee, PhD, MPH; Thomas Lodise, PharmD, PhD
Stakeholder Perspective
Love the Models, Send Me My Data: Conceptual Healthcare Decision Models Informing the Treatment of Acute Bacterial Skin and Skin Structure Infections
Michael F. Murphy, MD, PhD
Read More
Business, Original Research
Healthcare Costs and Absenteeism Among Caregivers of Adults with Partial-Onset Seizures: Analysis of Claims from an Employer Database
Richard A. Brook, MS, MBA; Krithika Rajagopalan, PhD; James E. Smeeding, RPh, MBA
Stakeholder Perspective
The Importance of Clinical and Economic Support Systems for Caregivers
Michael Kleinrock
Read More
Business, Original Research
Computed Tomography Colonography Less Costly Than Colonoscopy for Colorectal Cancer Screening of Commercially Insured Patients
Tia Goss Sawhney, DrPH, FSA, MAAA; Bruce S. Pyenson, FSA, MAAA; David Rotter, PhD; Michele Berrios; Judy Yee, MD
Read More
Business, Original Research
Alternative Payment Models in Medical Oncology: Assessing Quality-of-Care Outcomes Under Partial Capitation
Derek Ems, MPH; Sharanya Murty, PhD; Bryan Loy, MD; Judith Gallagher, MBA; Laura E. Happe, PharmD, MPH; Teresa L. Rogstad, MPH; Debra Finnel; Jimmy D. Fernandez, MD, MBA
Read More
Business, Original Research
Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes
Ivar S. Jensen, MBA; Elizabeth Wu, MPH; Naomi C. Sacks, PhD; Philip L. Cyr, MPH; Karen C. Chung, PharmD, MS
Read More
Business, Original Research
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly
Sameer R. Ghate, PhD; Zhiyi Li, MBA, MA; Jackson Tang, MSc; Antonio Reis Nakasato, MD
Stakeholder Perspective
It’s About the Total Cost of Care
Gary M. Owens, MD
Read More
Business, Original Research
Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies
Vincent J. Willey, PharmD; Sheldon Kong, PhD; Bingcao Wu, MS; Amit Raval, PhD; Todd Hobbs, MD; Andrea Windsheimer, PharmD; Gaurav Deshpande, MS, PhD; Ozgur Tunceli, PhD; Brian Sakurada, PharmD; Jonathan R. Bouchard, MS, RPh
Read More
Business, Original Research
The Prevalence and Payer Costs of Potentially Avoidable Emergent Care Visits for Suspected Amniotic Membrane Rupture in Pregnant Women
Christine Ferro, CHFP; Bruce S. Pyenson, FSA, MAAA; Jocelyn Lau, MPH; Mona Kelkar, MBA; Nancy Phillips, MD; Chi-Wei Lu, PhD; Percy Yeung, PhD; Gloria Bachmann, MD
Stakeholder Perspective
Interventions to Reduce Avoidable Pregnancy-Related Emergency Department Visits
Eliza Ng, MD
Read More
Business, Original Research
Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease
Michele Wilson, MSPH; Aaron Lucas, PhD, MPH; Ann Cameron, MA, PhD; Michelle Luo, PhD
Read More
Page 4 of 16
Results 31 - 40 of 155